Prediction of Molecular Targets of Cancer Preventing Flavonoid Compounds Using Computational Methods by Chen, Hanyong et al.
Prediction of Molecular Targets of Cancer Preventing
Flavonoid Compounds Using Computational Methods
Hanyong Chen
1., Ke Yao
1., Janos Nadas
1., Ann M. Bode
1, Margarita Malakhova
1, Naomi Oi
1, Haitao Li
1,
Ronald A. Lubet
2, Zigang Dong
1*
1The Hormel Institute, University of Minnesota, Austin, Minnesota, United States of America, 2The National Cancer Institute, Bethesda, Maryland, United States of
America
Abstract
Plant-based polyphenols (i.e., phytochemicals) have been used as treatments for human ailments for centuries. The
mechanisms of action of these plant-derived compounds are now a major area of investigation. Thousands of
phytochemicals have been isolated, and a large number of them have shown protective activities or effects in different
disease models. Using conventional approaches to select the best single or group of best chemicals for studying the
effectiveness in treating or preventing disease is extremely challenging. We have developed and used computational-based
methodologies that provide efficient and inexpensive tools to gain further understanding of the anticancer and therapeutic
effects exerted by phytochemicals. Computational methods involving virtual screening, shape and pharmacophore analysis
and molecular docking have been used to select chemicals that target a particular protein or enzyme and to determine
potential protein targets for well-characterized as well as for novel phytochemicals.
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Introduction
The consumption of fruits and vegetables has long been
believed to decrease the risk of developing various types of human
cancers [1]. A major class of compounds within foods that possess
these activities are the polyphenols [2]. The phenylpropanoid
metabolic pathways of plants generate these polyphenolic com-
pounds from thousands of secondary plant metabolites [3].
Flavonoids are the most common family of polyphenolic
compounds with up to 8,000 individual compounds identified
[4]. Flavonoids found in vegetables, cereals, legumes, fruits, and
beverages such as wine, teas, and coffees can be subdivided into 14
different categories based on chemical structure. These categories
include the chalcones, dihydrochalcones, aurones, flavones,
flavonols, dihydroflavonols, flavanones, flavanols, flavandiols,
anthocyanidins, isoflavonoids, biflavonoids, and proanthocyani-
dins [5].
The anticarcinogenic potential of a variety of well-characterized
flavonoids has been well documented [1]. Isoflavonoids, such as
anthraquinones, chalcones, and prenylflavonoids, are all capable
of promoting estrogenic activity in mammals [6]. They have also
been shown to possess anticancer properties [7]. Genistein, for
example, a major member of the isoflavonoid family derived from
soybeans [7], specifically inhibits the epidermal growth factor
receptor (EGFR) tyrosine kinase activity, which plays an important
role in cell proliferation and transformation [8]. New findings
continue to be reported related to these compounds. Resveratrol, a
polyphenol found in red wine, is known to possess antioxidant
activities as well as anticancer activities explained by its inhibition
of the cyclooxygenase proteins [9]. Recently, we reported that
resveratrol can suppress leukotriene A4 hydrolase (LTA4H) activity
[10], which is over-expressed in lung and colon cancer cells [11].
Flavonoids are promiscuous in that they can suppress the
growth of many different types of cancer cells through a variety of
mechanisms. This nonspecificity is compounded by the fact that
thousands of flavonoids exist and therefore their study has
provided a very rich area of research. Only a few cases of
computational work focusing on flavonoids exist [12,13,14]. Using
conventional methods to select the best single or group of best
chemicals for identifying compounds that are effective in on
treating or preventing a disease like cancer is difficult. Compu-
tational strategies for determining protein targets of flavonoids
have not yet received a great deal of attention. Over the last 3
years, our laboratory has utilized computational strategies that
include virtual screening, shape similarity-screening, and molec-
ular docking to identify potential protein targets of flavonoids and
other phytochemicals [15]. These computational-based method-
ologies have provided efficient and inexpensive tools to gain
further understanding of the anticancer and therapeutic effects
exerted by polyphenols. Herein we present our process for
combining those computational strategies with experimental
methodologies for validating specific flavonoids and their respec-
tive protein targets.
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Virtual Screening
Virtual screening is a computational technique used in drug
discovery research in recent years and it has become an
important step in the drug discovery process. The screening
involves the identification and compilation of relevant chemical
structures from large chemical libraries. The chemicals identified
are those most likely to bind to a protein target, typically a
protein receptor selected by using various computer programs
or identified experimentally. Virtual screening by molecular
docking is the major computational method employed in drug
discovery for ‘‘hit’’ identification [16]. The primary methodol-
ogy used is structure-based virtual screening, which involves
docking of thousands of candidate ligands into a protein target
followed by scoring the protein-ligand binding interaction to
estimate the binding energy of the ligand [17]. Structure-based
virtual screening requires the 3D structure of the ligands. The
ZINC (i.e., an acronym for ‘‘ZINC is not commercial’’)
Database contains over 13 million purchasable compounds in
3D docking format that are freely available for virtual screening
[18]. From this huge database, smaller and more specific high-
quality libraries can be built for targeted virtual screening [19].
Another available database containing 2D forms of molecules is
the National Institute of Health’s PubChem online database
comprising over 27 million unique structures (http://pubchem.
ncbi.nlm.nih.gov/). In our laboratory, we have created a smaller
flavonoid compound database of 2,620 compounds, including
aurones, chalcones, flavones, flavanones, isoflavones, biflavo-
noids, anthocyanidins, dihydrochalcones and proanthocyanidins.
These flavonoid compounds were collected and compiled from
the NCI PubChem database using structure based searching.
This database was used in the screening for potential inhibitors
targeting a number of cancer-related proteins, including p90
ribosomal S6 kinase 2 (RSK2), cyclin dependent kinase (Cdk),
mitogen-activated protein kinase kinase 1 (MEK1), epidermal
growth factor receptor (EGFR) and phosphatidylinositol 3-
kinase/protein kinase B (PI3-K/PKB).
The Ras/extracellular signal-regulated kinase (ERK) pathway
regulates cell proliferation, survival, growth and motility and
tumorigenesis [20]. RSK2, a member of the p90RSK family, is a
direct substrate kinase of ERKs and is an important direct effector
for transcriptional activation of downstream target transcription
factors. Furthermore, RSK2 is reportedly involved in prostate
cancer cell proliferation [21] and c-fos–dependent osteosarcoma
development [22]. RSK2 protein abundance is increased in many
human cancer cell lines and in various human skin tumors,
including melanomas and squamous cell carcinomas [23].
Therefore, identifying a selective RSK2 inhibitor is extremely
important for chemoprevention or therapeutic drug development.
Therefore, herein we used RSK2 as an example to demonstrate
how computational strategies and experimental methodologies can
be combined effectively to identify selective flavonoid inhibitors.
To date, a number of potential RSK2 inhibitors have been
reported, including eriodictyol [24] and kaempferol [23,25,26],
two flavonoid compounds and SL0101, a synthesized compound
not found in plants [27]. These flavonoids are ubiquitously found
in fruits and vegetables as well as popular beverages, including
wine, tea, and coffee and exhibit antioxidant, antitumor, and anti-
inflammatory effects [28].
Our laboratory has solved and reported the crystal structures of
the C-terminal and N-terminal kinase domains of RSK2 [29,30].
The N-terminal kinase domain was bound with ANP at the ATP
binding site. Thus, this structure (PDB ID:3G51) was downloaded
from the PDB Bank for virtual screening studies. Crystal structures
or homology models of the target protein to which a small
molecule will be docked are downloaded from the Protein
Databank (PDB). Waters, metals, and ligands are then stripped
from the structure and hydrogens and atom charges are added to
the structures using the protein preparation module in Schro ¨din-
ger’s Maestro v9.2 GUI. An ATP binding site-based pocket was
generated within a 30-A ˚ 3 grid. The 2D structure database of
flavonoids was converted to a 3D structure database using the
LigPrep module of the Schro ¨dinger Suite of software.
High throughput virtual screening (HTVS) and docking are
usually performed first because they are intended for the rapid
screening of large numbers of ligands followed by standard and
extra precision (SP and XP) docking. Here, for our flavonoid
database, only SP and XP docking were performed because of the
smaller number of ligands involved. All compounds were docked
flexibly and a top-20 list of compounds was generated and
organized based on the docking score (i.e., lower score is best). A
list of the top-6 ranked compounds was compiled (Table 1) and
kaempferol (Fig. 1A) and quercetin (Fig. 1B) were purchased for
experimental validation. Kaempferol and quercetin are natural
flavonols found in apples, onions and other plants.
Shape-Similarity Screening Method
The theory of shape-similarity screening is derived from the idea
that molecules possessing similar shapes and electrostatic capabil-
ities might exhibit analogous biological activity. The method
involves consideration of the atomistic and spatial characteristics
of the target molecule. The pharmacophore and physical features
of the molecule are quantitatively compared with a library of
compounds. When searching for potential target proteins, the
compound library used is composed of crystallized ligands
extracted from the most recent version of the PDB [31]. The
ligand conformation in the crystal structure is used because
Table 1. Results of virtual screening for RSK2 inhibitors.
Compound Name Docking Score (kcal/mol) Activity Validation
Pedalitin 210.20 *
Quercetin 3-sulfate 29.93 *
Quercetin 29.40 Yes
5-Hydroxy-49-methoxy-7-methylflavone 29.28 *
Kaempferol 28.86 Yes
3,39-di-O-ethylquercetin 28.50 *
*, Not commercially available.
doi:10.1371/journal.pone.0038261.t001
Computational Strategies Finding Protein Targets
PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e38261the atoms are oriented in a manner optimized for binding to the
protein. Any available database can be used when searching for
similar compounds.
The PHASE [32] module of Schro ¨dinger’s molecular modeling
software package is one program that can perform this type of
shape-similarity search [33]. The atom type information is
included for consideration of not only shape similarity but also
to align potential pharmacophore points between the queries and
targets. The cutoff to be used for the results takes the top aligned
structure for each molecule returned and all conformers possessing
a Tanimoto similarity coefficient below 0.7 are deleted [34,35].
The smaller flavonoid compound database that we created and the
latest version of the PDB, which contains more than 500,000
protein structures complexed with ligands, were used for shape-
similarity screening. We also created a specific kinase database of
about 4,000 structures complexed with ligands that we collected
from the PDB for screening kinase targets separately.
Our previous studies showed that myricetin (Fig. 1C), a
flavonoid found in many grapes, berries, fruits, vegetables, herbs,
as well as other plants, and one of the phenolic compounds present
in red wine, exhibits potent anticancer and chemopreventive
effects, especially on UVB-induced skin cancer [36], but its
molecular mechanisms and targets are unclear. Thus, to identify
off-target protein affected by myricetin, shape-similarity screening
was performed using the PDB ligand database and our special
kinase database.
Figure 1. Chemical structures. (A) Chemical structure of kaempferol; (B) Chemical structure of quercetin. (C) Chemical structure of myricetin. (D)
Chemical structure of LY294002. (E) Chemical structure of isorhamnetin.
doi:10.1371/journal.pone.0038261.g001
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which is a well known kinase involved in cellular functions such as
growth, proliferation, differentiation, motility, survival and intra-
cellular trafficking, all of which are associated with cancer
development. Wortmannin and LY294002 are broad inhibitors
that target all PI3-K family members. LY294002 (Fig. 1D) is a
morpholine derivative of quercetin and although its IC50 is about
500-fold higher than that of wortmannin, it is still widely used in
cell biology as a specific PI3-K inhibitor because of its stability in
solution [37]. We therefore used the structure of LY294002 to
carry out the screening for potential PI3-K inhibitors in our
flavonoid database using the PHASE module of the Schro ¨dinger
Suite 2011. To perform the screening, myricetin and LY294002
were first prepared separately using the LigPrep module of the
Schro ¨dinger Suite 2011 under the OPLS_2005 force field and a
specifying pH value of 7.0. Then shape-similarity screening was
carried out using PHASE.
Molecular Docking Method
Molecular docking has become a standard tool in computa-
tional biology for predicting the binding orientation of small
molecule drug candidates with their protein targets in order to
predict the affinity and activity of the small molecule. Thus,
molecular docking plays an important role in the rational design of
drugs. GLIDE from the Schro ¨dinger Suite 2011 [38] is one of the
programs used in our laboratory to perform docking.
Different protocols for docking are attempted before determin-
ing the correct set of parameters to be used for docking. The
correct re-docking of the ligand that was crystallized with the
target protein is typically used as validation of the chosen
parameters. When more than one crystal structure of a target
protein is available, cross-docking is performed to determine which
crystal structure is most suitable for docking [39].
In our laboratory, we had found that isorhamnetin (Fig. 1E), an
O-methylated flavonol in herbal medicinal plants such as red
turnip, goldenrod, mustard leaf and gross Hippophaer hamnoides L.,
could inhibit the kinase activity of MEK1 or PI3-K and the
inhibition was due to isorhamnetin’s direct binding with these
kinases [40]. Molecular docking was used to further study the
binding of isorhamnetin with MEK1. First an X-ray structure of
the human MEK1 in a complex with ligand and MgATP (PDB
1S9J) with a 2.4 A ˚ resolution was downloaded from the PDB. The
protein was prepared for docking using the Protein Preparation
Wizard. All crystallographic waters were deleted and a 30-A ˚ 3 grid
was generated based on the ATP noncompetitive ligand (BBM)
binding site of the protein receptor. MacroModel was used to
build and energetically minimize isorhamnetin to create the most
energetically favorable conformation needed for docking studies.
Several standard procedures included in Schro ¨dinger’s GLIDE
docking protocols were performed. Procedures included docking
with standard precision (SP) or extra precision (XP) in GLIDE,
and the more CPU-intensive Induced-Fit Docking (IFD) method
with the default parameters were conducted with SP and XP
Figure 2. Quercetin binds with RSK2 and inhibits RSK2 activity in vitro. (A) Quercetin binds at the ATP pocket of RSK2 most likely in an ATP-
competitive manner. (B) RSK2 binds with quercetin. A lysate prepared from JB6 C41 cells or commercially available active RSK2 was incubated with
Sepharose 4B-quercetin beads or with Sepharose 4B beads alone, and the pulled down proteins were analyzed by Western blot. (C) Quercetin binds
with either the NTD or the CTD of RSK2. To identify the RSK2 domain that binds with quercetin, RSK2 proteins, as indicated, were incubated with
Sepharose 4B-quercetin beads or with Sepharose 4B beads alone. The pulled down proteins were analyzed by Western blot. (D) Active RSK2 (10 ng)
was combined with GST-NFAT3-261-365 (2 mg), 10 mM unlabeled ATP, 10 mCi [c-
32P]ATP, and different doses of quercetin (0–50 mM). An in vitro
kinase assay was performed and the
32P-labeled phosphorylated NFAT3 was visualized by autoradiography. Band density was quantified using the
Image J software program (NIH) and the band intensity of active RSK2 and GST-NFAT3-261-365 (100%) was compared.
doi:10.1371/journal.pone.0038261.g002
Table 2. Potential kinase targets of myricetin.
Protein PDB ID Ligand Code
Shape Similarity
Score Reported Inhibitor
Average Similarity
Score Hits
Pim-1 2O3P QUE 0.90 yes 0.82 8**
2O63 MYC 0.88 yes
2O64 MYU 0.86 yes
GSK-3b 3DU8 553 0.83 yes 0.79 5**
1Q41 IXM 0.80 yes
3ZRL ZRL 0.78 yes
PI3-K* 3PRZ 3RZ 0.81 yes 0.77 6**
3DPD 41A 0.79 yes
3PS6 3PS 0.78 yes
Cdk2 1E1V CMG 0.83 yes 0.76 16**
1H0W 207 0.82 yes
1E1X NW1 0.80 yes
Raf* 3PPJ FOI 0.73 yes 0.72 2
3C4C 324 0.71 yes
MEK1* 3EQH ADP 0.71 yes 0.71 1
*, Protein targets that been validated in our laboratory.
**, Only the top 3 hits are shown here.
doi:10.1371/journal.pone.0038261.t002
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flexibility and a total of 20 top ranked structures were analyzed
using the IFD method.
Results
Virtual Screening
Based on our virtual screening results for RSK2, quercetin and
kaempferol have binding scores of 29.40 kcal/mol and
28.86 kcal/mol, respectively, with RSK2 (Table 1). These scores
are a very good indication of binding compared with 27.73 kcal/
mol for SL0101, a well-known RSK2 inhibitor. Our docking
model shows quercetin binding in an ATP-competitive manner
within the ATP banding site of RSK2 (Fig. 2A), indicating that
quercetin might also be a potential inhibitor of RSK2. To examine
our hypothesis, we conjugated quercetin with Sepharose 4B beads
and conducted an in vitro pull-down assay using a whole cell lysate
or an active RSK2 protein (200 ng; Fig. 2B). The results showed
that the RSK2 protein bound with Sepharose 4B-quercetin beads
but not with Sepharose 4B beads alone (Fig. 2B). Furthermore, we
conducted a pull-down assay with Sepharose 4B-quercetin beads
and several bacterially-expressed His-tagged RSK2 protein
fragments, including His-RSK2-1-740, His-RSK2-1-373, His-
RSK2-328-740, and His-RSK2-399-740. Western blot results
indicated that both the NTD and CTD of RSK2 bound with
Sepharose 4B-quercetin beads (Fig. 2C). To confirm the results of
the virtual screening that identified quercetin as a potential RSK2
inhibitor, we conducted an in vitro kinase assay. Results indicated
that quercetin inhibited RSK2 activity in a dose-dependent
manner (Fig. 2D). We previously used an in vitro kinase assay, an
anchorage-independent cell transformation assay and a pull-down
assay with Sepharose 4B-kaempferol beads to show that
kaempferol binds with the NTD of RSK2 and inhibits RSK2
activity in vitro and ex vivo [23,26,31].
Shape-Similarity Screening. In our study, the shape-
similarity screening was performed using Schro ¨dinger’s PHASE
module to examine the database comprised of protein complexes
with ligands and the specific kinase database. Myricetin, a
flavonoid found in grapes, berries, fruits, vegetables, herbs, as
well as other plants, and a phenolic compounds present in red
wine, was determined to target many potential kinases (Table 2).
The data indicate six different kinase/ligand complexes with an
average score of shape-similarity with myricetin greater than 0.7.
The ligand with the greatest similarity to myricetin is QUE or
quercetin (Fig. 1B), which is bound with Pim-1 (PDB ID: 2O3P).
The similarity score is 0.90 and quercetin is a reported inhibitor of
Pim-1 [41]. A total of 8 Pim-1 structures were ‘‘hit’’ by myricetin
with a similarity score of greater than 0.7 (only the top 3 hits are
shown in Table 2). Almost all the ‘‘hit’’ ligands are reported
inhibitors of their targeted kinase and have a similarity score of
greater than 0.7. Thus, we believe that these related kinases might
be possible targets of myricetin and that myricetin might
potentially inhibit their activity. Our previous studies indicated
that myricetin could inhibit the activity of PI3-K, MEK1 and Raf
[36,42,43].
To find potential flavonoid inhibitors of PI3-K, LY294002, a
broad PI3-K inhibitor, was chosen to use as the query structure
and shape-similarity screening was performed using our flavonoid
database and the PHASE module. Similarity coefficients below
0.75 were deleted and 6 of the top ranked candidate compounds
are listed (Table 3). We have previously validated myricetin [42]
and isorhamnetin [40] as direct inhibitors of PI3-K.
Molecular Docking
To examine the molecular mechanism of the inhibition of
MEK1 by isorhamnetin and to understand how isorhamnetin
interacts with MEK1, we docked isorhamnetin in silico to the ATP-
noncompetitive binding pocket of MEK1 using several protocols
in the Schro ¨dinger Suite of software. By studying all the models
returned, we found that isorhamnetin formed some favorable
connections and docked nicely within the MEK1 ATP-noncom-
petitive binding site. Some important hydrogen bonds were
formed between isorhamnetin and the backbone of MEK1,
including Val127 in the ATP-noncompetitive binding site and
Ser212 in the activation loop. Isorhamnetin also formed hydro-
phobic interactions with the side chain at Ile99, Phe129, Ile141,
Phe209 and Leu118 (Fig. 3A,B). These results would render
MEK1 catalytically inactive by stabilizing the inactive conforma-
tion of the activation loop. Note that some images were generated
with the UCSF Chimera program [44].
Discussion
Thousands of individual flavonoid compounds exist in various
vegetables, fruits, and other plants. Flavonoids, such as catechins
found in strawberries and green and black teas, kaempferol from
brussel sprouts and apples, and quercetin from beans, onions and
apples, are believed to exert anti-inflammatory and anticancer
activities. For example, all of these compounds reportedly might
reduce the risk of developing lung cancer [45]. Flavonoids inhibit
many different types of cancers through a variety of mechanisms
and thousands of flavonoids exist, which makes the screening of
their potential anticancer effects and identification of their specific
protein targets extremely challenging using conventional ap-
proaches. Fortunately, the development of computational simula-
tion techniques and other computational strategies has simplified
and streamlined the overall process. Virtual screening can easily
generate results from all flavonoid compounds that can bind with
and affect the activity of a specific protein target. Shape-screening
can assist in finding potential ‘‘off-target’’ proteins of a specific
flavonoid compound. Molecular docking methods can provide a
better indication of how a compound interacts with its protein
target and influence the activity of the targeted protein. These
three processes can lead to the rapid discovery of potential lead
compounds for anticancer treatment and chemoprevention.
In recent years, with the help of the Blue Gene/L [46,47]
supercomputer from IBM, our laboratory has studied the
effectiveness and mechanisms of several lead flavonoid com-
pounds in cancer chemoprevention and treatment by using
computational simulation strategies. These compounds include
kaempferol [23], isorhamnetin [40], 6,7,49-trihydroxyisoflavone
[48], eriodictyol [24], 7,39,49-trihydroxyisoflavone [49], quercetin
[50], EGCG [51], [6]-gingerol [52], myricetin [36], coffee
Table 3. Sixflavonoid candidate inhibitors for PI3-K.
Compound Name Shape Similarity Score Validation
Mitoflaxone 0.84 *
Dimeflin 0.83 *
Isowogonin 0.76 *
Kumatakenin 0.76 *
Myricetin 0.75 Yes
Isorhamnetin 0.75 Yes
*, Not commercially available.
doi:10.1371/journal.pone.0038261.t003
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PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e38261Figure 3. Modeling of isorhamnetin binding with MEK1. (A) Isorhamnetin binds to an ATP-noncompetitive pocket of MEK1. The box indicates
an enlarged view. Hydrogen bonds are formed between isorhamnetin and the backbone of MEK1 (Val127 in the ATP-noncompetitive binding site
and Ser212 in the activation loop). (B) Ligand interaction diagram of the MEK1 and isorhamnetin complex. Residues are represented as colored
spheres, labeled with the residue’s name and number. The colors indicate the residue type (green = hydrophobic; blue = polar). The solid pink line
shows the hydrogen bond between the ligand and the receptor. Hydrophobic interactions are formed with the side chain at Ile99, Phe129, Ile141,
Phe209 and Leu118.
doi:10.1371/journal.pone.0038261.g003
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[55]. All these compounds exert their inhibitory effect on specific
proteins, including RSK2, PI-3K, MEK1, Pin-1 and Fyn, which
are highly expressed or overactivated in some cancers such as
skin and colon cancer.
To identify the potential targets of a variety of flavonoid
compounds and to carefully study their mechanism of action, we
created a flavonoid database of 2,620 compounds. We are
continuing to enlarge the database by adding more and more
flavonoid compounds. Based on this database, we have obtained
results for every compound and its potential off-target proteins by
using shape-similarity screening. We have more than 4.1 million
records for all kinds of protein targets and 374,000 records for the
specific kinase targets. These results can be easily queried by
compound identification or by protein type. We have also
screened for lead compounds targeting several specific kinase
targets related to skin cancer, colon cancer and lung cancer using
virtual screening and will use these results for further mechanistic
studies in cancer chemoprevention and therapy.
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